The absence and downregulation of CRBN expression in human myeloma cell lines result in IMiDs resistance, which is also supported by downregulation of CRBN expression at the time of lenalidomide resistance in MM patients [5]. The gene discussed is CRBN; the disease is plasma cell myeloma.